MedTrace Logo

Interindividual Variability in Duration of Action of Rocuronium in Pediatric Patients

NCT05529420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2024-11-21

No results posted yet for this study

Summary

Muscle relaxants represent an important part of general anesthesia in adult and pediatric patients. Their role is to facilitate intubation and enable some surgical interventions.

At our workplace, monitoring of the depth of neuromuscular blockade is a standard procedure in accordance with the 2017 recommendation of ČSARIM entitled "Principles of Patient Safety in Anesthesiology" \[1,2\]. At present, we mainly use rocuronium. One of the advantages of this non-depolarizing steroidal muscle relaxant with a rapid onset and intermediate duration of action is the existence of the specific antagonist sugammadex.

Conditions

  • Muscle Relaxation

Interventions

OTHER

measurement of the depth of neuromuscular blockade

time of TOF 1 measurement (= clinical effect, stimulation of the ulnar nerve - adductor pollicis muscle tension) will be documented in the CRF and if there is no need to add further doses of the muscle relaxant, TOF 2, TOF 3, TOF 4, and TOF-R ≥ 0,9 (= time to full recovery from the effect of the non-depolarizing muscle relaxant) will also be registered.

Sponsors & Collaborators

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Petr Stourac, prof. MD., Ph.D., MBA · Department of paediatric anaesthesia and intensive care medicine

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2023-08-31
Completion
2023-09-01

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05529420 on ClinicalTrials.gov